Nuronox

ApprovedSmall molecule

RRoongroj Bhidayasiri

Nuronox is one of 22 small molecule programs targeting Cervical Dystonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

Cervical DystoniaApproved

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Cervical Dystonia

#DrugCompanyPhaseTrials

Botox

AbbVie

Approved

3 2

BOTULINUM TOXIN TYPE B

Eisai

Approved

1 3

Dysport

Ipsen

Approved

1 4

Xeomin

MMerz Therapeutics GmbH

Approved

2 5

NT 201

MMerz Pharmaceuticals GmbH

Approved

1 6

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

1 7

Ingrezza

Neurocrine Biosciences

Phase 2

1 8

Marinol

Alnylam Pharmaceuticals

Phase 2

1 9

Meditoxin

MMedy-Tox

Phase 3

2 10

Fycompa

CCatalyst Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cervical Dystonia1 trial

The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients

Unknown status·RRoongroj Bhidayasiri·Phase 4·NCT01664013·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nuronox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nuronox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nuronox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roongroj Bhidayasiri company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RRoongroj Bhidayasiri

Nuronox

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cervical Dystonia1 trial

References

Drug Info

Quick Facts

Related News